Peritoneal carcinoma metastatic occurs when cancer spreads from its original location to the peritoneum, the thin membrane lining the inside of your abdomen and covering your organs. Understanding when and how this condition is diagnosed can make a significant difference in treatment planning and outcomes.

Introduction: Who Should Consider Diagnostic Testing

People who should undergo diagnostic testing for peritoneal carcinoma metastatic include those already diagnosed with cancers that commonly spread to the peritoneum. These primary cancers typically originate in organs within or near the abdominal cavity. The most common sources include ovarian cancer, which is the most frequent cause, followed by cancers of the colon, stomach, pancreas, appendix, and rectum. In rare cases, cancers from organs outside the abdominal cavity can also spread to the peritoneum, though this happens in only about 10% of cases.^[2]

If you have been diagnosed with any of these cancers, your medical team may recommend diagnostic testing even if you feel well, because peritoneal metastases often do not cause symptoms in the early stages. Many people experience no warning signs until the cancer has affected a large portion of the peritoneal membrane. This is why doctors consider it important to actively look for peritoneal spread in patients with high-risk primary cancers.^[1]

It is advisable to seek diagnostic evaluation if you experience certain symptoms that could indicate peritoneal involvement. The most common symptom is abdominal swelling or bloating, particularly when it seems unrelated to diet or exercise. This swelling occurs because of fluid accumulation in the abdomen, a condition called ascites (pronounced ah-SIGH-teez), which means abnormal fluid buildup in the belly. Other symptoms that should prompt you to see your doctor include persistent abdominal pain or discomfort that feels like cramping or pressure, unexplained weight loss or paradoxical weight gain in the abdomen, a feeling of fullness after eating only small amounts, ongoing fatigue, nausea and vomiting, changes in bowel habits such as constipation, and low back pain.^[3]

Women in menopause who notice their abdomen appearing pregnant or people who find themselves gaining weight specifically in the belly despite maintaining their usual activity level should consider consulting their healthcare provider. Similarly, if you experience ongoing digestive issues that do not improve with standard treatments, or if you notice an abdominal mass you can feel through your skin, these warrant medical evaluation.^[3]

Classic Diagnostic Methods

The diagnosis of peritoneal carcinoma metastatic typically requires multiple tests because the condition often spreads across the abdominal lining without forming distinct, easily visible masses. Doctors usually need to combine several diagnostic approaches to confirm the presence and extent of the disease.^[8]

Imaging Tests

Imaging tests are typically the first step when doctors suspect peritoneal carcinoma metastatic. These scans help identify visible tumor spread, fluid buildup, or organ involvement. The most commonly used imaging test is a CT scan (computed tomography scan), which uses X-rays and computer technology to create detailed cross-sectional images of your abdomen. CT scans are considered the method of choice because they are widely available, cost-effective, and have relatively high sensitivity in detecting peritoneal metastases. During this test, you lie still on a table that moves through a doughnut-shaped machine that takes multiple images from different angles.^[5]

MRI (magnetic resonance imaging) scans use powerful magnets and radio waves instead of radiation to create detailed images of your abdominal cavity. The sensitivity of MRI depends significantly on the size of peritoneal implants. For lesions larger than 10 millimeters (about the size of a small grape), MRI sensitivity is comparable to CT. MRI may be particularly useful in certain situations where soft tissue detail is important.^[5]

Some studies suggest that PET scans (positron emission tomography), particularly PET-CT which combines two imaging technologies, may be among the most sensitive methods for detecting peritoneal carcinomatosis. PET scans involve injecting a small amount of radioactive sugar into your vein, which cancer cells absorb more readily than normal cells, making them visible on the scan. However, the usefulness of PET scans in everyday clinical practice remains somewhat controversial, and they are not always routinely used.^[5]

An important limitation of imaging tests is that they are often not sensitive enough to detect smaller cancers or early peritoneal disease. This means that a negative scan does not completely rule out peritoneal carcinomatosis. Small tumor deposits may be present even when imaging appears normal, which is why doctors may recommend additional testing methods.^[8]

Blood Tests

Your doctor may order blood tests to check for tumor markers, which are substances that tumors release into the bloodstream. High levels of certain proteins in your blood may indicate the presence of peritoneal carcinomatosis. The specific tumor markers tested depend on the type of primary cancer suspected or known to be present. These blood tests provide supporting evidence but typically cannot diagnose peritoneal metastases on their own.^[2]

A newer type of blood test called circulating tumor DNA (ctDNA) looks for small pieces of DNA from cancer cells floating in the blood. This test can help identify peritoneal cancer that does not show up on scans. However, this technology is still relatively new and may not be available everywhere.^[8]

Paracentesis

If you have ascites (fluid buildup in your abdomen), your doctor may perform a procedure called paracentesis to remove a sample of this fluid. During this procedure, the doctor inserts a thin needle through your abdominal wall to withdraw fluid, which is then sent to a laboratory. Scientists examine the fluid under a microscope and test it for signs of the primary cancer that has spread. This can help confirm the diagnosis and identify what type of cancer is present. Even when imaging does not show visible tumors, finding cancer cells in the fluid is a strong sign that peritoneal spread has occurred.^[2]

Peritoneal Washing Cytology

Peritoneal washing cytology involves collecting fluid from the abdominal cavity during a minor surgical procedure and examining it under a microscope. Healthcare professionals use this test to check for cancer cells floating in the peritoneal fluid. This differs from paracentesis in that it is performed surgically rather than through a simple needle insertion. Even when no visible cancer is present during surgery, a positive cytology result provides strong evidence that peritoneal spread has happened.^[8]

Staging Laparoscopy

Staging laparoscopy is a safe, minimally invasive surgical procedure that allows doctors to look directly inside your abdominal cavity using a small camera. The surgeon makes small incisions in your abdomen and inserts a thin tube with a camera attached. This procedure enables healthcare professionals to inspect the peritoneum directly, find hidden tumors that imaging might have missed, and take tissue or fluid samples for laboratory analysis. This test is especially valuable for finding peritoneal metastases that are too small to be detected with imaging scans. Because it provides direct visualization, it is often considered one of the most reliable methods for detecting early or small peritoneal deposits.^[8]

Biopsy

A biopsy involves removing a small sample of tumor tissue so it can be tested in a laboratory for cancer cells. This can be done during laparoscopy or through other surgical approaches. The tissue sample is examined by a pathologist who can confirm whether cancer is present and identify its characteristics. A biopsy provides definitive proof of cancer and helps determine the specific type, which guides treatment decisions.^[2]

Physical Examination

Your doctor will begin with a physical examination, which can sometimes reveal important clues. On physical examination, your surgeon may be able to feel tumor nodules in the abdomen or detect fluid accumulation. While a physical exam alone cannot diagnose peritoneal carcinomatosis, it helps your doctor understand your symptoms and decide which tests to order next.^[6]

Peritoneal Carcinomatosis Index

The Peritoneal Carcinomatosis Index (PCI) is a specialized scoring system that your healthcare provider may use during the diagnostic process to assess the extent of disease and plan treatment. Using this index, doctors map the location of tumors in your abdomen and small intestine during surgery or laparoscopy. They divide the abdomen into 13 regions and assign each region a score from 0 to 3 based on the size of tumor deposits found there. The scores from all regions are added together to give a total PCI score ranging from 0 to 39.^[2]

This information helps your healthcare team understand how extensively the cancer has spread and whether surgery to remove visible tumors is likely to be successful. The PCI serves as both a diagnostic tool and a communication method between clinicians and radiologists, ensuring everyone on your care team has the same understanding of your disease burden.^[5]

Diagnostics for Clinical Trial Qualification

When patients with peritoneal carcinoma metastatic are being considered for enrollment in clinical trials, specific diagnostic tests and criteria are used to determine eligibility. Clinical trials often have strict requirements about the extent and characteristics of disease that participants must meet.

Imaging studies such as CT scans and MRI are standard requirements for clinical trial enrollment. These scans establish baseline measurements of disease extent, which researchers use to track whether experimental treatments are working. Most clinical trials require recent imaging, typically performed within a few weeks before enrollment, to ensure the information is current.^[5]

The Peritoneal Carcinomatosis Index is frequently used in clinical trials as a standardized measure of disease burden. Trials may specify maximum PCI scores for enrollment, as some experimental treatments are designed for patients with lower disease burdens. Having a documented PCI score allows researchers to group patients with similar disease severity and compare outcomes more accurately across different study participants.^[5]

Blood tests measuring tumor markers are commonly required for clinical trial qualification. These tests establish baseline levels that can be monitored throughout the trial to assess treatment response. Different trials focus on different markers depending on the type of primary cancer involved. Researchers track whether these marker levels increase, decrease, or remain stable during treatment.^[2]

Histopathological confirmation through biopsy is almost always mandatory for clinical trial enrollment. Trials need to verify not only that cancer is present but also its specific type and characteristics at the cellular level. This tissue analysis may include testing for specific genetic mutations or protein expressions that the experimental treatment targets. For example, some trials only accept patients whose tumors have particular genetic features that make them likely to respond to the treatment being studied.^[4]

Performance status assessment is another standard criterion for clinical trial qualification. Doctors evaluate how well you can perform daily activities and care for yourself. Most trials require patients to have relatively good functional status, meaning they can walk around and take care of their basic needs without significant assistance. This is assessed using standardized scales that measure your overall health and ability to tolerate treatment.^[4]

Laboratory tests evaluating organ function are routinely required before clinical trial enrollment. These tests check how well your kidneys, liver, bone marrow, and other organs are working. Trials often exclude patients whose organs are not functioning well enough to safely process experimental treatments. Blood tests measuring kidney function, liver enzymes, blood cell counts, and other markers provide this information.^[4]

Some clinical trials require laparoscopy before enrollment to directly visualize and measure peritoneal disease. This provides more accurate assessment than imaging alone and allows doctors to take multiple tissue samples from different areas. Laparoscopy-based scoring systems help researchers select patients with the most appropriate disease characteristics for the experimental treatment being tested.^[4]